Misplaced Pages

Odesivimab is a Zaire ebolavirus glycoprotein-directed human monoclonal antibody that is part of the fixed-dose combination atoltivimab/maftivimab/odesivimab that is used for the treatment of Zaire ebolavirus (Ebola virus).

References

1. "FDA Approves First Treatment for Ebola Virus". U.S. Food and Drug Administration (FDA) (Press release). 14 October 2020. Retrieved 14 October 2020. This article incorporates text from this source, which is in the public domain.
2. "Regeneron's Antibody Cocktail REGN-EB3 (Inmazeb) is First FDA-Approved Treatment for Ebola (Zaire Ebolavirus)". Regeneron Pharmaceuticals Inc. (Press release). 14 October 2020. Retrieved 14 October 2020.

External links

• "Odesivimab". Drug Information Portal. U.S. National Library of Medicine.
• "Statement on a nonproprietary name adopted by the USAN Council USAN (FG-102) Odesivimab" (PDF).

• Medicine
• Viruses

This antiinfective drug article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Drugs not assigned an ATC code
• Ebola
• Monoclonal antibodies
• Antiinfective agent stubs